KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Gross Profit (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Gross Profit for 8 consecutive years, with $68.7 million as the latest value for Q4 2025.

  • Quarterly Gross Profit fell 2.04% to $68.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $273.2 million through Dec 2025, changed 0.49% year-over-year, with the annual reading at $273.2 million for FY2025, 0.49% changed from the prior year.
  • Gross Profit hit $68.7 million in Q4 2025 for Castle Biosciences, up from $64.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $72.5 million in Q2 2024 to a low of $19.0 million in Q3 2021.
  • Historically, Gross Profit has averaged $45.2 million across 5 years, with a median of $44.6 million in 2023.
  • Biggest five-year swings in Gross Profit: soared 86.33% in 2023 and later fell 8.31% in 2025.
  • Year by year, Gross Profit stood at $20.4 million in 2021, then soared by 40.97% to $28.8 million in 2022, then surged by 86.33% to $53.7 million in 2023, then skyrocketed by 30.6% to $70.1 million in 2024, then dropped by 2.04% to $68.7 million in 2025.
  • Business Quant data shows Gross Profit for CSTL at $68.7 million in Q4 2025, $64.3 million in Q3 2025, and $68.6 million in Q2 2025.